IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

IGC Pharma (NYSE American: IGC) received authorization in Colombia on April 9, 2026 to synthesize, formulate, and develop psilocybin at its Bogotá R&D facility under Fondo Nacional de Estupefacientes oversight.

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) received authorization in Colombia on April 9, 2026 to synthesize, formulate, and develop psilocybin at its Bogotá R&D facility under Fondo Nacional de Estupefacientes oversight.

The capability lets IGC evaluate psilocybin for neuropsychiatric symptoms (NPS) in dementia, including depression and anxiety, while its lead program IGC-AD1 (CALMA Phase 2) is ~80% enrolled and remains the company’s near-term priority.

Positive

• Regulatory authorization: Colombia approval to synthesize and develop psilocybin (April 9, 2026)
• Strategic platform: Capital-efficient capability to evaluate novel neuropsychiatric approaches
• Clinical progress: CALMA Phase 2 trial ~80% patient enrollment for IGC-AD1

Negative

• Near-term focus constraint: CALMA remains the primary near-term priority, limiting immediate psilocybin program progress
• No revenue impact disclosed: Announcement does not provide commercial timelines or financial guidance for psilocybin work

Argus Apr 20 session

-5.03% close to close Open Argus

Details

News Market Reaction – IGC

On Apr 20, the day this news came out, IGC closed 5.03% below the previous close.

Data tracked by StockTitan Argus for the Apr 20 session.

Market Context

On Apr 20, the day this news came out, the stock closed 5.0% below the previous close. A negative re...

Analysis

On Apr 20, the day this news came out, the stock closed 5.0% below the previous close. A negative reaction despite this expansion into psilocybin research would contrast with prior generally positive responses to CALMA and awareness milestones, where 24-hour moves were modestly higher on four of the last five news events. A pullback could reflect concern about execution risk, funding needs, or complexity added to the pipeline rather than the authorization itself, especially given the company’s clinical-stage status and previously disclosed working capital deficit.

Key Figures

CALMA enrollment: approximately 80% NPS prevalence: about 80% of Alzheimer’s patients Alzheimer’s market burden: $1 trillion

CALMA enrollment

approximately 80%

Phase 2 CALMA trial for agitation in Alzheimer’s disease

NPS prevalence

about 80% of Alzheimer’s patients

Neuropsychiatric symptoms such as agitation, depression, anxiety

Alzheimer’s market burden

$1 trillion

CEO’s reference to overall Alzheimer’s disease crisis scale

Historical Context

5 past events · Latest: Apr 14

5 events

1. Apr 14

   CALMA enrollment update

   24h Move

   +4.4%

   Reported ~80% enrollment in Phase 2 CALMA trial for Alzheimer’s agitation.

2. Apr 08

   Analyst target change

   24h Move

   +3.5%

   Equity research firm raised price target citing clinical progress and 2026 catalysts.

3. Apr 07

   Trial site expansion

   24h Move

   +0.9%

   Activated new CALMA trial site with enrollment reported over 70% complete.

4. Mar 30

   Media partnership

   24h Move

   +0.1%

   Launched 12-part national media campaign to expand investor awareness.

5. Mar 19

   Earnings and clinical

   24h Move

   -1.3%

   Filed 10-KT with improved net loss, CALMA progress, and detailed financial position.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

psilocybin, neuropsychiatric symptoms (NPS)

2 terms

psilocybin medical

"received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin"

A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.

neuropsychiatric symptoms (NPS) medical

"psilocybin, for example in neuropsychiatric symptoms (NPS) associated with dementia"

Neuropsychiatric symptoms are changes in mood, behavior, thinking or perception—such as agitation, depression, anxiety, hallucinations or apathy—that arise from brain disorders or injuries. Investors should care because these symptoms influence clinical trial outcomes, product safety profiles, treatment demand and healthcare costs, acting like visible warning lights that shape a therapy’s market size, regulatory review and commercial success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion

POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that on April 9, 2026, it received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá.

The authorization, granted under the oversight of the Fondo Nacional de Estupefacientes (FNE), provides IGC Pharma with a regulated capability to work with psilocybin, positioning the Company within an expanding area of scientific and investor interest. The Company believes it is among a limited number of organizations in Colombia with this type of authorization.

This capability allows the Company to evaluate potential applications of psilocybin, for example in neuropsychiatric symptoms (NPS) associated with dementia, including depression and anxiety, conditions affecting a large portion of Alzheimer's patients and representing a significant and underserved market opportunity.

Potential Engine of Growth

Neuropsychiatric symptoms affect about 80% of Alzheimer's patients and broad and heterogeneous, including agitation, depression, anxiety, and mood-related conditions. While IGC Pharma's lead candidate, IGC-AD1, is advancing through a Phase 2 clinical trial targeting agitation, additional symptom domains such as depression and anxiety represent a substantial and largely unaddressed segment of the disease burden. The Company believes that differentiated mechanisms may be required across these symptom clusters, creating the potential for multiple therapeutic pathways.

Strategic Positioning in a High-Growth Area

The psilocybin authorization provides IGC Pharma with a capital-efficient platform to evaluate emerging therapeutic approaches in neuropsychiatric disorders. Compared to traditional drug development pathways, this capability allows for earlier-stage evaluation with greater flexibility and lower cost. This authorization also positions the Company within a rapidly evolving global landscape, where regulatory, scientific, and investor interest in novel neuropsychiatric therapies continues to expand. Early access to regulated development environments may provide a strategic advantage as this field matures.

Complementary to CALMA Clinical Program

The Company continues to prioritize the advancement of its lead program, IGC-AD1, currently being evaluated in the Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease, which has recently reached approximately 80% patient enrollment and is advancing toward completion.

"IGC-AD1 and CALMA remains our primary near-term focus as we advance toward data readout," said Ram Mukunda, CEO of IGC Pharma. "At the same time, we are not just targeting agitation, we are building a multi-pronged approach to the $1 trillion Alzheimer's crisis. This authorization allows us to build additional assets in Alzheimer's disease using differentiated mechanisms in a capital-efficient manner."

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to the Company's ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes, demonstrate safety and efficacy, the timing of data readouts, regulatory approvals, and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-KT. The Company undertakes no obligation to update these statements.

Contact Information:

Walter Frank / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IGC (IGC) authorize in Colombia on April 9, 2026?

IGC received authorization to synthesize, formulate, and develop psilocybin at its Bogotá R&D facility. According to the company, the permit from Fondo Nacional de Estupefacientes enables regulated preclinical and development activities with psilocybin.

How does the psilocybin authorization affect IGC's Alzheimer's research pipeline (IGC)?

The authorization provides a capital-efficient platform to explore psilocybin for NPS in dementia. According to the company, it complements IGC-AD1 efforts and allows evaluation of additional mechanisms for depression and anxiety in Alzheimer's patients.

What is the status of IGC-AD1 and the CALMA Phase 2 trial (IGC)?

IGC-AD1's CALMA Phase 2 trial is approximately 80% enrolled and advancing toward completion. According to the company, CALMA remains the primary near-term focus ahead of an expected data readout.

Will IGC's psilocybin work create immediate revenue for shareholders (IGC)?

No immediate revenue is disclosed from the psilocybin authorization. According to the company, the permission enables early-stage evaluation rather than near-term commercial launches or revenue recognition.

Why is psilocybin relevant for neuropsychiatric symptoms in dementia for IGC (IGC)?

Psilocybin may address depression and anxiety, common NPS in Alzheimer's patients affecting about 80% of cases. According to the company, these symptom domains are substantial and largely underserved, representing development opportunities.